JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Simulations Plus Inc

Gesloten

SectorGezondheidszorg

17.15 -2.5

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

17.15

Max

18.24

Belangrijke statistieken

By Trading Economics

Inkomsten

-70M

-67M

Verkoop

-2.1M

20M

K/W

Sectorgemiddelde

48.528

37.461

Dividendrendement

0.48

Winstmarge

-330.585

Werknemers

243

EBITDA

-79M

-74M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

-9.19% downside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.48%

2.33%

Volgende Winsten

29 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-28M

323M

Vorige openingsprijs

19.65

Vorige sluitingsprijs

17.15

Nieuwssentiment

By Acuity

63%

37%

328 / 371 Rangschikking in Healthcare

Simulations Plus Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 okt 2025, 20:49 UTC

Winsten

Correction to Thermo Fisher Article on Oct. 22

23 okt 2025, 23:51 UTC

Marktinformatie

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 okt 2025, 23:49 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

23 okt 2025, 23:49 UTC

Marktinformatie

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 okt 2025, 23:37 UTC

Marktinformatie

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 okt 2025, 22:58 UTC

Marktinformatie

Global Energy Roundup: Market Talk

23 okt 2025, 22:57 UTC

Marktinformatie

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 okt 2025, 22:49 UTC

Acquisities, Fusies, Overnames

How Trump Sparked a New Era of State Capitalism -2-

23 okt 2025, 22:49 UTC

Acquisities, Fusies, Overnames

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 okt 2025, 22:17 UTC

Winsten

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 okt 2025, 21:41 UTC

Winsten

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 okt 2025, 21:05 UTC

Winsten

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 okt 2025, 20:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

23 okt 2025, 20:50 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

23 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

23 okt 2025, 20:35 UTC

Winsten

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 okt 2025, 20:28 UTC

Winsten

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 okt 2025, 20:15 UTC

Marktinformatie
Winsten

Global Commodities Roundup: Market Talk

23 okt 2025, 20:10 UTC

Winsten

Newmont Mining 3Q Adj EPS $1.71

23 okt 2025, 20:10 UTC

Winsten

Newmont Mining 3Q Sales $5.52B

23 okt 2025, 20:10 UTC

Winsten

Newmont Mining 3Q EPS $1.67

23 okt 2025, 20:09 UTC

Winsten

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 okt 2025, 20:07 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

23 okt 2025, 20:07 UTC

Marktinformatie
Winsten

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 okt 2025, 20:07 UTC

Winsten

Blackstone Looks to IPOs for Investment Exits -- Update

23 okt 2025, 20:05 UTC

Winsten

Intel 3Q Gross Margin 38.2% >INTC

23 okt 2025, 20:04 UTC

Winsten

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 okt 2025, 20:04 UTC

Winsten

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 okt 2025, 20:04 UTC

Winsten

Intel: 4Q Guidance Excludes Altera >INTC

23 okt 2025, 20:04 UTC

Winsten

Intel Sees 4Q Adj EPS 8c >INTC

Peer Vergelijking

Prijswijziging

Simulations Plus Inc Prognose

Koersdoel

By TipRanks

-9.19% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 16 USD  -9.19%

Hoogste 16 USD

Laagste 16 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Simulations Plus Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Sentiment

By Acuity

328 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat